Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies

May 29-31, 2020; Online at meetings.asco.org/am
Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.
Format: Microsoft PowerPoint (.ppt)
File Size: 240 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff P. Sharman, MD Released: April 26, 2022

An expert provides commentary and recommendations on the clinical needs of HCPs in treating CLL with BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: April 25, 2022

Review an expert commentary on investigational treatment strategies for CLL, from Clinical Care Options (CCO)

person default Shuo Ma, MD, PhD Released: April 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings